Eiger BioPharmaceuticals, Inc. (EIGR) At $14.55 Forms Bottom; RIVAL TECHNOLOGIES (RVTI) Shorts Decreased By 35.29%

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger BioPharmaceuticals, Inc. (EIGR) formed multiple bottom with $13.68 target or 6.00% below today’s $14.55 share price. Eiger BioPharmaceuticals, Inc. (EIGR) has $199.86 million valuation. The stock increased 0.69% or $0.1 during the last trading session, reaching $14.55. About 120,554 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has risen 88.41% since June 17, 2017 and is uptrending. It has outperformed by 75.84% the S&P500. Some Historical EIGR News: ; 24/05/2018 – Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stk; 17/05/2018 – Eiger Biopharmaceuticals: Elucidating The Fundamentals Powering A Gargantuan Winner; 16/05/2018 – Eiger Announces Expanded License Agreement With Merck for Investigational Candidate Lonafarnib and Collaboration With the Progeria Research Foundation; 25/05/2018 – EIGER BIOPHARMACEUTICALS CONFIRMS OFFERING PRICE $12.50/SHARE; 23/04/2018 – European Medicines Agency Validates Type Il Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3…; 23/03/2018 – Krka’s Pemetrexed Krka Gets Generic Recommendation in Europe; 15/05/2018 – 683 Capital Management Buys 1.9% Position in Eiger BioPharma; 17/04/2018 – Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in; 17/04/2018 – EIGER ANNOUNCES SUB-ANALYSIS OF PHASE 2 RESULTS DEMONSTRATING HIGH RESPONSE RATES TO “ALL-ORAL” LONAFARNIB-RITONAVIR REGIMEN IN LOW VIRAL LOAD HDV-INFECTED PATIENTS AT THE INTERNATIONAL LIVER; 19/04/2018 – Ra Medical Systems Appoints Andrew Jackson as Chief Financial Officer

RIVAL TECHNOLOGIES INC (OTCMKTS:RVTI) had a decrease of 35.29% in short interest. RVTI’s SI was 1,100 shares in June as released by FINRA. Its down 35.29% from 1,700 shares previously. With 2,200 avg volume, 1 days are for RIVAL TECHNOLOGIES INC (OTCMKTS:RVTI)’s short sellers to cover RVTI’s short positions. The stock increased 39.37% or $0.0063 during the last trading session, reaching $0.0223. About 800 shares traded or 233.33% up from the average. Rival Technologies, Inc. (OTCMKTS:RVTI) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.82 earnings per share, up 38.35% or $0.51 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -2.38% EPS growth.

Rival Technologies, Inc. is engaged in the development and sale of ground breaking process for upgrading bitumen and heavy oil to synthetic crude oil in the United States. The company has market cap of $1.03 million. The Company’s primary upgrading process TRU takes heavy oil or bitumen at the field level and produces a pipeline grade synthetic crude oil to the oil producers. It currently has negative earnings. The firm was formerly known as North American Fire Guardian Technologies Inc.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart